Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TGM1 | P22735 | 1/20 | 0.45 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699681 | 0.84 | TGM2 (0.54) | TGM2THRATHRBF13A1LMNA | |
| SCHEMBL11208884 | 0.76 | GAA (0.64) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL18500990 | 0.75 | LMNA (0.65) | LMNA | |
| SCHEMBL1381808 | 0.73 | TGM2 (0.65) | TGM2THRATHRBF13A1LMNA | |
| SCHEMBL1132464 | 0.73 | THRA (0.67) | TGM2THRATHRBF13A1LMNA | |
| SCHEMBL27616728 | 0.72 | TDP1 (0.51) | TGM2THRATHRBF13A1LMNA | |
| SCHEMBL19386559 | 0.71 | GAA (0.36) | LMNA | |
| SCHEMBL25896984 | 0.71 | KCNK3 (0.65) | — | |
| SCHEMBL10033524 | 0.71 | TSHR (0.60) | TGM2THRATHRBF13A1LMNA | |
| SCHEMBL17660300 | 0.71 | EPHB4 (0.61) | TGM2EGFRFYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329297-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | IDO1, IDO2, INMT | TGM2 710/4885THRA 2276/4885THRB 1535/4885 |
| US-10329297-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | IDO1, IDO2, INMT | TGM2 710/4885THRA 2276/4885THRB 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.